In plain terms: Glucosamine Sulfate shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Glucosamine Sulfate
The evidence as the record states it
Graded by salt and by endpoint. Reginster et al. (Lancet, 2001; PMID 11214126) and Pavelka et al. (Arch Intern Med, 2002; PMID 12374520): two 3-year randomized placebo-controlled trials of crystalline glucosamine sulfate 1,500 mg/day; joint-space narrowing slowed and symptom scores improved against placebo. Hughes and Carr (Rheumatology, 2002; PMID 11934964): 6-month randomized trial of the same sulfate dose in 80 patients; no difference from placebo on pain. Fransen et al. (Ann Rheum Dis, 2015; PMID 24395557, LEGS): 2-year randomized trial, 605 participants; glucosamine sulfate alone did not change joint-space narrowing or pain, and only the glucosamine plus chondroitin combination reduced narrowing (0.10 mm). Clegg et al. (New England Journal of Medicine, 2006; PMID 16495392, GAIT): 24-week randomized trial, 1,583 patients; glucosamine hydrochloride alone did not reduce pain (P=0.30). Li et al. (Annals of the Rheumatic Diseases, 2020; PMID 32253185) and King et al. (2020; PMID 33219063): prospective cohorts associating regular glucosamine use with lower mortality; observational, so they inform context and carry no grade. Grade C: two positive and two null randomized trials of the sulfate, with the positive pair sharing one manufacturer-supplied product, and a null trial of the hydrochloride. Hawkinson et al. (Nat Metab, 2026; PMID 42265388): in Alzheimer's mouse models oral glucosamine worsened cognitive outcomes, and in a retrospective review of electronic health records, patients with Alzheimer's disease who had glucosamine recorded progressed faster and survived less long. Nakashima et al. (medRxiv preprint, 2026; PMID 42619916), testing the same question in the National Alzheimer's Coordinating Center cohort, found a similar progression estimate for multivitamin and calcium plus vitamin D records, and no excess mortality with glucosamine, which suggests the record is marking the patient rather than the supplement. Animal plus health-record association, not yet peer reviewed on the rebuttal side; it carries no grade.
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.